Twist Bioscience Launches $250M Stock Offering, Diluting Existing Holders
TWST has more than doubled off its 52-week low of $23.3.
Summary
Twist Bioscience is tapping public markets for $250 million via an underwritten common stock offering, with a 30-day option for an additional $37.5 million. The deal follows a June shelf registration that included a $200 million ATM program, but this is a firm commitment offering with specific terms and named bookrunners (Goldman Sachs, William Blair, Leerink, Guggenheim). Proceeds are earmarked for R&D, manufacturing expansion, and working capital. At a $6.2 billion market cap, the offering represents roughly 4% dilution before the overallotment, a meaningful but not crippling raise. The stock closed at $98.01; pricing details are pending, but the announcement alone may pressure shares as the market absorbs the supply overhang. No pricing or timing guarantees were given, leaving execution risk.
At the time of this announcement, TWST was trading at $98.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $23.30 to $106.58. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.